EGAGenomicsRNASeqhttps://ega-archive.org/studies/EGAS00001007601EGAEGA study EGAS00001007601PRADO trial - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab plus nivolumab in stage III melanomaEGArestrictedGH05739, Radiation Treatments, Ribonucleic, Biological Markers, Viral Marker, ONO-4538, Node, Surrogate Endpoints, Targeted Radiation Therapy, Metastasis, Clinical Markers, Laboratory, BMS 936558, Clinical Marker, developmental stage, MDX CTLA 4, Radiation Therapies, Biochemical, BMS936558, Endpoint, MDX-010, Neoplasm Metastases, neoplasm metastasis, Serum, Malignant, cancer metastasis, Lymph Node Dissection, Surrogate End Points, melanoma (disease), Surrogate Markers, Excision, Laboratory Markers, III, GH14582, melanoma, Biological, Gene Products, 3, ONO 4538, Non Polyadenylated, Lymph, Excisions, DmelCG2043, treatment, MDX010, Biomarker, tumor cell migration, MDX-CTLA-4, lcp3, Clinical, Lymph Node Dissections, MDX-1106, Naevocarcinoma, Biological Marker, LCP-3, Lymph Node Excisions, Radiotherapies, metastasis, Opdivo, Targeted Radiotherapies, RNA Gene Products., MDX 010, Non-Polyadenylated RNA, ONO4538, Immunologic Markers, Immune, CP3, Markers, Clients, Viral Markers, disease management, Therapies, stage, CG7776, Targeted Radiotherapy, Immunologic Marker, tumor metastasis, Biologic, MDX1106, Node Dissection, Therapy, Dissections, X-ray therapy, RNA, Anti-CTLA-4 MAb, LcpIII, Radiation, Viral, Targeted Radiation, Surrogate Endpoint, Targeted Radiation Therapies, ribose nucleic acid, malignant, lymphatic system, Metastases, Serum Markers, e(Pc), ribonucleic acids, Targeted, End Point, Biochemical Markers, RNS, Malignant Melanomas, Biologic Marker, L[[3]]CP3, Client, Dissection, Immune Marker, Metastase, MDX 1106, Melanomas, Node Dissections, Melanoma, Marker, Surrogate End Point, Radiotherapy, yeast nucleic acid, Malignant Melanoma, Ribonukleinsaeure, Neoplasm, Anti CTLA 4 MAb Ipilimumab, pentosenucleic acids, Ribonucleic acids, radiation therapy, LCP3, Anti-CTLA-4 MAb Ipilimumab, nodus lymphaticus, Biologic Markers, ribonucleic acid, Acid, Serum Marker, Ipilimumab, DmelCG7776, DMLCP3, End Points, Lymph Node, l(2)28-28-12, Surrogate, Non Polyadenylated RNA, Endpoints, Lymphadenectomy, Non-Polyadenylated, anon-35Fa, radioisotope therapy, Radiation Treatment, Immunologic, Ribonucleic Acid, Laboratory Marker, Treatments, Surrogate Marker, DmelCG5861, Lymph node, Therapeutic, Patient, anon-35Fc, Biochemical Marker, BMS-936558, DmelLcp3, E(PC), Indexes, BG:DS02740.11, anon-48Ac, Nodes, Radiation Therapy, Lymphadenectomies, Treatment, malignant melanoma, lymph gland, CG2043, Yervoy, Immune MarkersTherapy, GH05739, Anti-CTLA-4 MAb, ONO-4538, LcpIII, BMS 936558, malignant, developmental stage, e(Pc), MDX CTLA 4, BMS936558, intraoperative procedures, MDX-010, Surgery, Malignant Melanomas, Naevocarcinoma., Malignant, L[[3]]CP3, MDX 1106, melanoma (disease), Melanomas, Melanoma, III, peroperative procedures, GH14582, melanoma, Malignant Melanoma, Anti CTLA 4 MAb Ipilimumab, 3, General, preoperative procedures, LCP3, ONO 4538, Anti-CTLA-4 MAb Ipilimumab, DmelCG2043, treatment, MDX010, MDX-CTLA-4, Ipilimumab, DmelCG7776, lcp3, DMLCP3, l(2)28-28-12, operative therapy, MDX-1106, LCP-3, operations, anon-35Fa, Opdivo, Treatments, MDX 010, ONO4538, DmelCG5861, CP3, Therapeutic, anon-35Fc, BMS-936558, DmelLcp3, E(PC), BG:DS02740.11, anon-48Ac, disease management, perioperative procedures, Therapies, Treatment, malignant melanoma, stage, CG7776, operative procedures, CG2043, Yervoy, invasive procedures, MDX1106falsePRADO trial - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab plus nivolumab in stage III melanomaThe PRADO trial tested a personalized response-directed treatment approach based on the pathologic response after neoadjuvant ipilimumab plus nivolumab in stage III melanoma patients. In patients achieving a major pathologic response, in their index lymph node (the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted. Patients with partial response underwent TLND only, whereas patients with pathologic non-response underwent TLND and adjuvant systemic therapy ± synchronous radiotherapy. Biomarker analyses based on baseline RNA sequencing data were performed in order to find features that are associated with major pathologic response.2023-11-21 15:35:38EGAS000010076019606EGAD00001012116EGAC00001003455